TruBridge (TBRG)
Market Price (6/22/2026): $26.1 | Market Cap: $380.1 MilSector: Health Care | Industry: Health Care Technology
TruBridge (TBRG)
Market Price (6/22/2026): $26.1Market Cap: $380.1 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% Attractive yieldFCF Yield is 7.9% Low stock price volatilityVol 12M is 42% Megatrend and thematic driversMegatrends include Cloud Computing, Digital Health & Telemedicine, and Cybersecurity. Themes include Software as a Service (SaaS), Show more. | Trading close to highsDist 52W High is -0.2% Weak multi-year price returns3Y Excs Rtn is -69% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x, P/EPrice/Earnings or Price/(Net Income) is 86x Weak revenue growthRev Chg QQuarterly Revenue Change % is -1.1% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.1% Key risksTBRG key risks include [1] a material weakness in its internal controls over financial reporting and [2] market saturation and client consolidation within its specific rural and community hospital niche. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Attractive yieldFCF Yield is 7.9% |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Cloud Computing, Digital Health & Telemedicine, and Cybersecurity. Themes include Software as a Service (SaaS), Show more. |
| Trading close to highsDist 52W High is -0.2% |
| Weak multi-year price returns3Y Excs Rtn is -69% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x, P/EPrice/Earnings or Price/(Net Income) is 86x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -1.1% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.1% |
| Key risksTBRG key risks include [1] a material weakness in its internal controls over financial reporting and [2] market saturation and client consolidation within its specific rural and community hospital niche. |
Qualitative Assessment
AI Analysis | Feedback
TruBridge (TBRG) stock has gained about 35% since 2/28/2026 because of the following key factors:
1. Acquisition by IKS Health. TruBridge announced a definitive agreement on April 23, 2026, to be acquired by Inventurus Knowledge Solutions, Inc. (IKS Health) for $26.25 per share in cash. This acquisition, expected to close in the third quarter of 2026, provided a clear and substantial premium to the stock's trading price before the announcement, significantly driving the stock's upward movement. The stock price jumped from approximately $22.88 on April 22, 2026, to $25.76 on April 23, 2026, following this news.
2. Strong First Quarter 2026 Earnings Beat. On May 8, 2026, TruBridge reported its first quarter 2026 earnings, posting an Earnings Per Share (EPS) of $0.59. This figure surpassed analysts' consensus estimates, which ranged from $0.51 to $0.57, indicating better-than-expected financial performance for the period ending March 31, 2026. While quarterly revenue was slightly below estimates at $86.27 million, the EPS beat contributed positively to investor sentiment.
Show more
TruBridge (TBRG) stock has gained about 35% since 2/28/2026 because of the following key factors:
1. Acquisition by IKS Health. TruBridge announced a definitive agreement on April 23, 2026, to be acquired by Inventurus Knowledge Solutions, Inc. (IKS Health) for $26.25 per share in cash. This acquisition, expected to close in the third quarter of 2026, provided a clear and substantial premium to the stock's trading price before the announcement, significantly driving the stock's upward movement. The stock price jumped from approximately $22.88 on April 22, 2026, to $25.76 on April 23, 2026, following this news.
2. Strong First Quarter 2026 Earnings Beat. On May 8, 2026, TruBridge reported its first quarter 2026 earnings, posting an Earnings Per Share (EPS) of $0.59. This figure surpassed analysts' consensus estimates, which ranged from $0.51 to $0.57, indicating better-than-expected financial performance for the period ending March 31, 2026. While quarterly revenue was slightly below estimates at $86.27 million, the EPS beat contributed positively to investor sentiment.
3. Positive Analyst Sentiment and Price Target Revisions. Prior to the acquisition announcement, analysts had a cautiously optimistic outlook, with an average target price of $22.67 and a potential upside of 27.34% as of March 12, 2026. Following the acquisition announcement, some analysts adjusted their ratings to "Hold" with a price target of $26.25 by April 24, 2026, aligning with the acquisition price. This revised target price further validated the stock's near-term valuation and provided a floor for its price, reinforcing investor confidence in the anticipated payout from the merger.
Show less
Stock Movement Drivers
Fundamental Drivers
The 35.3% change in TBRG stock from 2/28/2026 to 6/21/2026 was primarily driven by a 43.0% change in the company's Net Income Margin (%).| (LTM values as of) | 2282026 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.29 | 26.09 | 35.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 347 | 346 | -0.3% |
| Net Income Margin (%) | 0.9% | 1.3% | 43.0% |
| P/E Multiple | 90.8 | 86.3 | -4.9% |
| Shares Outstanding (Mil) | 15 | 15 | -0.3% |
| Cumulative Contribution | 35.3% |
Market Drivers
2/28/2026 to 6/21/2026| Return | Correlation | |
|---|---|---|
| TBRG | 35.3% | |
| Market (SPY) | 9.2% | 25.4% |
| Sector (XLV) | -6.4% | 23.4% |
Fundamental Drivers
The 18.8% change in TBRG stock from 11/30/2025 to 6/21/2026 was primarily driven by a 43.0% change in the company's Net Income Margin (%).| (LTM values as of) | 11302025 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.96 | 26.09 | 18.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 347 | 346 | -0.3% |
| Net Income Margin (%) | 0.9% | 1.3% | 43.0% |
| P/E Multiple | 103.4 | 86.3 | -16.5% |
| Shares Outstanding (Mil) | 15 | 15 | -0.3% |
| Cumulative Contribution | 18.8% |
Market Drivers
11/30/2025 to 6/21/2026| Return | Correlation | |
|---|---|---|
| TBRG | 18.8% | |
| Market (SPY) | 9.9% | 23.7% |
| Sector (XLV) | -4.4% | 18.2% |
Fundamental Drivers
The 9.0% change in TBRG stock from 5/31/2025 to 6/21/2026 was primarily driven by a 10.3% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.93 | 26.09 | 9.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 345 | 346 | 0.2% |
| P/S Multiple | 1.0 | 1.1 | 10.3% |
| Shares Outstanding (Mil) | 14 | 15 | -1.3% |
| Cumulative Contribution | 9.0% |
Market Drivers
5/31/2025 to 6/21/2026| Return | Correlation | |
|---|---|---|
| TBRG | 9.0% | |
| Market (SPY) | 28.1% | 22.0% |
| Sector (XLV) | 14.6% | 23.0% |
Fundamental Drivers
The 9.3% change in TBRG stock from 5/31/2023 to 6/21/2026 was primarily driven by a 177.5% change in the company's P/E Multiple.| (LTM values as of) | 5312023 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.86 | 26.09 | 9.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 335 | 346 | 3.3% |
| Net Income Margin (%) | 3.2% | 1.3% | -60.7% |
| P/E Multiple | 31.1 | 86.3 | 177.5% |
| Shares Outstanding (Mil) | 14 | 15 | -2.9% |
| Cumulative Contribution | 9.3% |
Market Drivers
5/31/2023 to 6/21/2026| Return | Correlation | |
|---|---|---|
| TBRG | 9.3% | |
| Market (SPY) | 85.7% | 22.6% |
| Sector (XLV) | 22.9% | 21.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TBRG Return | 9% | -7% | -59% | 76% | 12% | 18% | -3% |
| Peers Return | -1% | -30% | -43% | 70% | -27% | -20% | -61% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| TBRG Win Rate | 50% | 42% | 50% | 67% | 42% | 50% | |
| Peers Win Rate | 50% | 29% | 42% | 67% | 47% | 28% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| TBRG Max Drawdown | -24% | -27% | -68% | -32% | -37% | -38% | |
| Peers Max Drawdown | -44% | -50% | -67% | -49% | -56% | -36% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WAY, MDRX, CCLD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | TBRG | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -60.7% | -9.5% |
| % Gain to Breakeven | 154.5% | 10.5% |
| Time to Breakeven | 426 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -21.7% | -6.7% |
| % Gain to Breakeven | 27.7% | 7.1% |
| Time to Breakeven | 660 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -44.0% | -33.7% |
| % Gain to Breakeven | 78.5% | 50.9% |
| Time to Breakeven | 314 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -17.2% | -3.7% |
| % Gain to Breakeven | 20.8% | 3.9% |
| Time to Breakeven | 4 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -18.0% | -12.2% |
| % Gain to Breakeven | 22.0% | 13.9% |
| Time to Breakeven | 26 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -35.1% | -6.8% |
| % Gain to Breakeven | 54.2% | 7.3% |
| Time to Breakeven | 96 days | 15 days |
In The Past
TruBridge's stock fell -1.8% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 1.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TBRG | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -60.7% | -9.5% |
| % Gain to Breakeven | 154.5% | 10.5% |
| Time to Breakeven | 426 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -21.7% | -6.7% |
| % Gain to Breakeven | 27.7% | 7.1% |
| Time to Breakeven | 660 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -44.0% | -33.7% |
| % Gain to Breakeven | 78.5% | 50.9% |
| Time to Breakeven | 314 days | 140 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -35.1% | -6.8% |
| % Gain to Breakeven | 54.2% | 7.3% |
| Time to Breakeven | 96 days | 15 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -21.9% | -53.4% |
| % Gain to Breakeven | 28.0% | 114.4% |
| Time to Breakeven | 22 days | 1085 days |
In The Past
TruBridge's stock fell -1.8% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 1.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TruBridge (TBRG)
TruBridge (TBRG) is a healthcare information technology company that provides comprehensive software solutions and services primarily to the U.S. healthcare market and St. Maarten. The company's core offerings include patient management software, which helps identify and track patient information throughout the care process, and financial accounting software, used for business office applications and managerial decision-making. Additionally, TruBridge provides clinical software that automates record-keeping for various medical functions like laboratory, radiology, and pharmacy, alongside patient care and enterprise applications that support broader hospital operations.
Beyond its foundational software, TruBridge offers specialized platforms such as Centriq, an intuitive user interface designed to centralize and display patient data, and solutions specifically tailored for the post-acute care industry to enhance clinical and financial outcomes. The company also delivers a wide array of services including software and hardware support, education, revenue cycle management (RCM), consulting, and managed IT services, as well as patient engagement and encoder solutions. TruBridge primarily serves community hospitals, physician clinics, skilled nursing facilities, and assisted living facilities.
AI Analysis | Feedback
Here are 1-3 brief analogies for TruBridge:
The SAP or Oracle for healthcare IT solutions.
Like Epic or Cerner, but focused on community hospitals and post-acute care facilities.
AI Analysis | Feedback
- Healthcare IT Software Systems: Comprehensive software suites for patient management, financial accounting, clinical functions (e.g., laboratory, radiology, pharmacy), and enterprise-level operations.
- Centriq Platform: An intuitive user interface designed to centralize and display past and present patient information from various care areas.
- Post-Acute Care Solutions: Specialized software and support services aimed at improving data-driven clinical and financial outcomes for facilities like skilled nursing and assisted living.
- Revenue Cycle Management (RCM) Services: Products and services focused on optimizing financial processes, billing, and collections for healthcare providers.
- Managed IT Services & Support: Offerings encompassing software application support, hardware maintenance, managed information technology services, and educational programs.
- Consulting & Business Management Services: Expert guidance and solutions to assist healthcare organizations with operational efficiency and strategic decision-making.
- Patient Engagement & Encoder Solutions: Tools and systems developed to enhance patient interaction and streamline medical coding processes.
AI Analysis | Feedback
TruBridge (TBRG) sells primarily to other companies and organizations within the healthcare industry. Based on the provided description, its major customers fall into the following categories:
- Community hospitals
- Physician clinics
- Skilled nursing facilities
- Assisted living facilities
The provided information does not list specific names of customer companies, nor does it indicate that any of its customers are publicly traded companies for which symbols could be provided.
AI Analysis | Feedback
AI Analysis | Feedback
Chris Fowler, President and Chief Executive Officer
Chris Fowler joined TruBridge in 2000 and served in various roles until becoming VP of Business Services in 2008. In 2013, this division became TruBridge, LLC, where he became President. He was later appointed TruBridge's COO in 2015, and in 2022, he became President and CEO, also joining CPSI's Board of Directors.
Vinay Bassi, Chief Financial Officer
Vinay Bassi has served as TruBridge's CFO since 2024. He was previously CFO for Nielsen Holdings plc's Audience Measurement division and held senior operational and financial roles at Nielsen, including CFO to the COO and SVP of Corporate FP&A, Global M&A, and Investments. Before Nielsen, Bassi served as Vice President of Corporate Development and Strategy at Avaya Inc. He began his career as an Auditor at PricewaterhouseCoopers and also worked at Standard & Poor's and Citigroup.
Mike Daughton, Chief Business Officer
Michael (Mike) Daughton joined TruBridge in 2025, bringing over 25 years of leadership in healthcare solutions. He previously held senior commercial roles at Optum, M*Modal, and EnableComp. Daughton led commercial initiatives at M*Modal and AQuity that resulted in several transactions, including 3M's $1 billion acquisition of M*Modal's technology business and AQuity's acquisition by IKS Health.
David Harse, General Manager Patient Care
David Harse joined TruBridge in 2022 as General Manager of the Patient Care business unit. He previously worked as a senior-level leader at Healthmark and spent over 20 years in various roles with the EHR business at Cerner.
Merideth Wilson, General Manager Financial Health
Merideth Wilson joined the TruBridge team in 2025 as General Manager of the Financial Health business unit. She has over 25 years of healthcare technology leadership experience, most recently serving as Executive Vice President and General Manager at Experian.
AI Analysis | Feedback
Here are the key risks to TruBridge's business:
-
Intense Competition and Client Attrition: TruBridge operates in a highly competitive healthcare IT market, facing competition from larger entities and the potential for hospitals to develop in-house solutions. This competitive landscape can lead to market saturation in its target segment of community hospitals. TruBridge has experienced client attrition, particularly in its Centralized Business Office (CBO) renewals, with some clients opting to bring revenue cycle management (RCM) services back in-house or showing hesitancy regarding the company's offshore delivery model. This directly impacts revenue growth and market share.
-
Profitability Challenges and Execution Risk of Strategic Transition: Despite improvements in adjusted EBITDA and cash flow, TruBridge has reported negative earnings per share (EPS) and net losses in previous periods, indicating challenges in consistently achieving net profitability. The company is undergoing a strategic pivot, including transitioning to a subscription-based recurring revenue model and modernizing its technology offerings. This strategic shift introduces execution risks, such as potential disruption to legacy client relationships, slower-than-anticipated adoption of new offerings, and delayed deal implementations, which could adversely affect near-term revenue growth and overall profitability.
-
Regulatory and Reimbursement Challenges: As a provider of healthcare IT solutions and services, TruBridge is highly susceptible to legislative and regulatory uncertainties within the healthcare industry. Changes in healthcare funding, tariffs, and reimbursement policies can significantly impact the financial health and spending capacity of its client base (community hospitals and physician clinics), thereby affecting the demand for TruBridge's products and services.
AI Analysis | Feedback
One clear emerging threat for TruBridge is the accelerating industry-wide shift towards highly integrated, cloud-native electronic health record (EHR) and health information system (HIS) platforms. TruBridge offers a comprehensive suite of software systems and applications for patient management, financial accounting, clinical functions, and post-acute care. If these offerings are not inherently built upon a modern, unified cloud-native architecture, they risk being outcompeted by solutions that inherently provide superior scalability, seamless interoperability, advanced security, and a lower total cost of ownership. This technological paradigm shift, where healthcare providers increasingly seek to consolidate their IT infrastructure onto single, modern cloud-based ecosystems, could fundamentally challenge TruBridge's potentially more fragmented or legacy solution architecture.
AI Analysis | Feedback
TruBridge (TBRG) operates in several key addressable markets primarily within the United States, offering a range of healthcare information technology solutions and services. The company's main products and services include Revenue Cycle Management (RCM), Electronic Health Records (EHR) solutions, patient engagement solutions, managed IT services, and software for the post-acute care industry. The market sizes for these areas in the U.S. are as follows:
-
Overall U.S. Healthcare IT Market: The U.S. healthcare IT market was valued at approximately USD 182.09 billion in 2025 and is projected to reach around USD 566.48 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 13.44% from 2025 to 2034. Another estimate indicates the market was valued at USD 160.52 billion in 2024.
-
U.S. Revenue Cycle Management (RCM) Market: This market in the U.S. is estimated at USD 65.38 billion in 2025 and is projected to grow to approximately USD 195.92 billion by 2035, with a CAGR of 11.6% from 2026 to 2035.
-
Electronic Health Records (EHR) Solutions: Within the broader U.S. healthcare IT market, the Electronic Health Records (EHR)/EMR systems segment was a dominant component in 2024. While a specific standalone U.S. market size for EHRs is not consistently available, the adoption of EHRs in U.S. hospitals has significantly increased to 81.2%, with 65% of hospitals planning further investment in EHR functionality.
-
U.S. Patient Engagement Solutions Market: The U.S. patient engagement solutions market was valued at USD 7.40 billion in 2025. It is anticipated to increase to approximately USD 25.21 billion by 2034, growing at a CAGR of 14.68% from 2025 to 2034. Another report valued this market at USD 7.59 billion in 2024, with an expected CAGR of 19.77% from 2025 to 2030.
-
U.S. Managed IT Services for Healthcare: The managed services market specifically linked to healthcare in the United States is projected to exceed USD 18 billion by 2031, with healthcare being the fastest-growing vertical at a 12.24% CAGR.
-
Post-Acute Care Software Market: The global long-term post-acute care software market was valued at USD 5.91 billion in 2025 and is projected to reach USD 17.71 billion by 2035, expanding at an 11.6% CAGR from 2026 to 2035. North America is expected to hold a 37% share of this market by 2035.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for TruBridge (TBRG)
TruBridge (TBRG) anticipates several key drivers for its revenue growth over the next 2-3 years, primarily focusing on technological advancements, strategic expansion of its core services, and operational efficiencies.
- Technological Innovation and Digital Transformation: TruBridge is actively pursuing growth through technological innovation and digital transformation, particularly by integrating advanced AI capabilities into its Electronic Health Record (EHR) system. The company is also collaborating with Microsoft to integrate Microsoft Dragon Copilot. These initiatives are expected to enhance its healthcare IT solutions and drive recurring revenue growth through expanded Software-as-a-Service (SaaS) offerings and broader digital transformation efforts.
- Expansion of Revenue Cycle Management (RCM) Services and Strategic Client Acquisition: The company's Financial Health segment, which encompasses revenue cycle management (RCM) services, is a significant growth area. TruBridge projects revenue increases through solid organic growth in this segment, coupled with enhanced execution and client acquisition, particularly targeting the 200-400 bed hospital market. The company also focuses on expanding its core Complete Business Office (CBO) offerings and integrating contributions from acquisitions like Viewgol.
- Global Workforce Strategy and Offshore Expansion: TruBridge is committed to expanding its global workforce and offshore capabilities, aiming to double the percentage of clients supported by its global workforce to 60% by the end of 2025. This strategy is intended to optimize operations, enhance efficiency within its Financial Health segment, support a larger client base, and drive margin expansion through cost rationalization.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Repurchases
- TruBridge (formerly CPSI) conducted share repurchases during the third and fourth quarters of 2022.
- A waiver was obtained on November 8, 2023, to exclude the Q3 and Q4 2022 share repurchases from the fixed charge coverage ratio for compliance purposes.
Share Issuance
- During 2022, 2023, and 2024, performance share awards targeting an aggregate of 512,103 shares were granted to executive officers and key employees, contingent upon predefined performance criteria.
- Shareholders approved an increase of 1,850,000 shares available for issuance under the 2019 Incentive Plan on May 8, 2025.
Inbound Investments
- As of November 4, 2025, investment entities Camac Partners, Camac Capital, Camac Fund, and individual investor Eric Shahinian collectively owned 861,638 shares of TruBridge common stock, representing 5.7% of the company.
- In March 2024, company insiders purchased approximately $998,295 worth of shares.
- L6 Holdings Inc. and Pinetree Capital Ltd. made indirect share purchases in November 2025, with weighted average prices ranging from $20.42 to $20.84 per share.
Outbound Investments
- TruBridge acquired Viewgol and HRG to expand its revenue cycle management capabilities.
- The company divested American HealthTech (AHT) in January 2024, as part of a strategic portfolio refocusing.
Capital Expenditures
- Capitalized software development costs, a component of capital expenditures, were approximately $17.1 million in 2024, $23.1 million in 2023, and $19.1 million in 2022.
- The company's estimated capital expenditures are projected to be $16.86 million for 2025, $19.24 million for 2026, and $21 million for 2027.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| TruBridge Earnings Notes | 12/16/2025 | |
| Would You Still Hold TruBridge Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 18.47 |
| Mkt Cap | 0.5 |
| Rev LTM | 467 |
| Op Inc LTM | 13 |
| FCF LTM | 57 |
| FCF 3Y Avg | 10 |
| CFO LTM | 81 |
| CFO 3Y Avg | 23 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.1% |
| Rev Chg 3Y Avg | -1.8% |
| Rev Chg Q | 6.0% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | -2.3% |
| Op Inc Chg 3Y Avg | 72.0% |
| Op Mgn LTM | 6.5% |
| Op Mgn 3Y Avg | 4.8% |
| QoQ Delta Op Mgn LTM | -1.3% |
| CFO/Rev LTM | 20.7% |
| CFO/Rev 3Y Avg | 13.0% |
| FCF/Rev LTM | 14.8% |
| FCF/Rev 3Y Avg | 6.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Financial Health | 222 | 217 | 192 | 180 | 131 |
| Patient Care | 125 | 125 | 144 | 140 | 143 |
| Patient Engagement | 7 | 6 | |||
| Total | 347 | 342 | 336 | 327 | 281 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Financial Health | 40 | 37 | 23 | 35 |
| Patient Care | 29 | 19 | 21 | 23 |
| Depreciation expense | -1 | -1 | -2 | -2 |
| Stock-based compensation | -9 | -6 | -3 | -5 |
| Amortization of acquisition-related intangibles | -12 | -13 | -16 | -17 |
| Severance and other non-recurring charges | -13 | -15 | -22 | -5 |
| Amortization of software development costs | -13 | -15 | -8 | -3 |
| Deferred revenue and other acquisition-related adjustments | 0 | -0 | ||
| Impairment of goodwill | -36 | 0 | ||
| Impairment of trademark intangibles | -2 | 0 | ||
| Patient Engagement | -2 | |||
| Total | 21 | 6 | -46 | 23 |
Price Behavior
| Market Price | $26.09 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 05/21/2002 | |
| Distance from 52W High | -0.2% | |
| 50 Days | 200 Days | |
| DMA Price | $25.03 | $21.26 |
| DMA Trend | up | up |
| Distance from DMA | 4.2% | 22.7% |
| 3M | 1YR | |
| Volatility | 51.7% | 42.1% |
| Downside Capture | -22.45 | 78.64 |
| Upside Capture | 166.78 | 74.59 |
| Correlation (SPY) | 25.3% | 21.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.03 | 0.76 | 1.18 | 1.03 | 0.84 | 0.74 |
| Up Beta | -0.13 | 0.88 | 1.60 | 1.07 | 1.16 | 0.72 |
| Down Beta | 0.04 | 0.06 | 1.18 | 0.87 | 0.40 | 0.57 |
| Up Capture | 8% | 270% | 147% | 114% | 69% | 46% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 10 | 25 | 32 | 60 | 123 | 389 |
| Down Capture | -14% | -259% | 49% | 97% | 98% | 98% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 5 | 9 | 24 | 55 | 114 | 343 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TBRG | |
|---|---|---|---|---|
| TBRG | 12.9% | 42.0% | 0.40 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 23.1% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 21.3% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | -1.4% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -11.2% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 18.7% |
| Bitcoin (BTCUSD) | -40.0% | 42.4% | -1.08 | 14.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TBRG | |
|---|---|---|---|---|
| TBRG | -5.0% | 42.8% | 0.01 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 26.0% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 27.6% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 0.6% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | 3.5% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 27.9% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | 11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TBRG | |
|---|---|---|---|---|
| TBRG | -3.4% | 42.0% | 0.06 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 30.2% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 34.0% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 3.1% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 12.1% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 31.9% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | 11.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/8/2026 | 0.2% | 0.1% | 0.7% |
| 11/6/2025 | 0.9% | 6.1% | 17.4% |
| 8/8/2025 | 1.5% | 2.0% | 5.5% |
| 5/7/2025 | -2.0% | -2.9% | -6.6% |
| 3/10/2025 | 7.5% | 2.7% | -12.3% |
| 11/7/2024 | -0.1% | 15.5% | 36.8% |
| 8/8/2024 | 24.5% | 25.6% | 19.8% |
| 5/10/2024 | 4.3% | 10.0% | 16.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 14 | 12 |
| # Negative | 11 | 9 | 11 |
| Median Positive | 4.1% | 5.8% | 12.3% |
| Median Negative | -9.7% | -9.9% | -8.7% |
| Max Positive | 24.5% | 25.6% | 36.8% |
| Max Negative | -19.7% | -29.6% | -43.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/8/2026 | 0.2% | 0.1% | 0.7% |
| 11/6/2025 | 0.9% | 6.1% | 17.4% |
| 8/8/2025 | 1.5% | 2.0% | 5.5% |
| 5/7/2025 | -2.0% | -2.9% | -6.6% |
| 3/10/2025 | 7.5% | 2.7% | -12.3% |
| 11/7/2024 | -0.1% | 15.5% | 36.8% |
| 8/8/2024 | 24.5% | 25.6% | 19.8% |
| 5/10/2024 | 4.3% | 10.0% | 16.1% |
| 2/29/2024 | 3.7% | -8.9% | -5.0% |
| 11/8/2023 | -11.5% | -9.9% | -21.1% |
| 8/9/2023 | -19.7% | -29.6% | -43.9% |
| 5/9/2023 | -10.8% | -8.4% | -1.6% |
| 2/14/2023 | 3.9% | 5.8% | 0.2% |
| 11/1/2022 | -19.1% | -13.7% | -8.7% |
| 8/2/2022 | -10.7% | -9.3% | -9.2% |
| 5/3/2022 | 3.4% | 0.4% | 5.3% |
| 2/15/2022 | 4.8% | 5.8% | 19.9% |
| 11/9/2021 | -9.7% | -16.0% | -20.2% |
| 8/3/2021 | 6.9% | 8.1% | 13.7% |
| 5/10/2021 | -0.0% | 6.2% | 10.9% |
| 2/9/2021 | -5.4% | -14.7% | -5.1% |
| 11/5/2020 | -1.4% | 4.4% | 0.0% |
| 8/4/2020 | 5.0% | 3.1% | -0.8% |
| SUMMARY STATS | |||
| # Positive | 12 | 14 | 12 |
| # Negative | 11 | 9 | 11 |
| Median Positive | 4.1% | 5.8% | 12.3% |
| Median Negative | -9.7% | -9.9% | -8.7% |
| Max Positive | 24.5% | 25.6% | 36.8% |
| Max Negative | -19.7% | -29.6% | -43.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/15/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/15/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/15/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/12/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 03/11/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pinetree, Capital Ltd | See footnotes | Buy | 12032025 | 23.00 | 10,000 | 230,000 | 48,990,000 | Form | |
| 2 | Pinetree, Capital Ltd | See footnotes | Buy | 12032025 | 22.72 | 45,000 | 1,022,400 | 48,166,400 | Form | |
| 3 | Pinetree, Capital Ltd | See footnotes | Buy | 12032025 | 22.40 | 75,000 | 1,680,000 | 46,480,000 | Form | |
| 4 | Pinetree, Capital Ltd | See footnotes (3)(4)(5) | Buy | 11192025 | 20.70 | 8,501 | 175,971 | 17,595,000 | Form | |
| 5 | Pinetree, Capital Ltd | See footnotes (3)(4)(5) | Buy | 11192025 | 20.84 | 3,639 | 75,837 | 17,536,839 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pinetree, Capital Ltd | See footnotes | Buy | 12032025 | 23.00 | 10,000 | 230,000 | 48,990,000 | Form | |
| 2 | Pinetree, Capital Ltd | See footnotes | Buy | 12032025 | 22.72 | 45,000 | 1,022,400 | 48,166,400 | Form | |
| 3 | Pinetree, Capital Ltd | See footnotes | Buy | 12032025 | 22.40 | 75,000 | 1,680,000 | 46,480,000 | Form | |
| 4 | Pinetree, Capital Ltd | See footnotes (3)(4)(5) | Buy | 11192025 | 20.70 | 8,501 | 175,971 | 17,595,000 | Form | |
| 5 | Pinetree, Capital Ltd | See footnotes (3)(4)(5) | Buy | 11192025 | 20.84 | 3,639 | 75,837 | 17,536,839 | Form | |
| 6 | Pinetree, Capital Ltd | See footnotes (3)(4)(5) | Buy | 11192025 | 20.42 | 20,707 | 422,837 | 17,109,101 | Form | |
| 7 | Daughton, Michael | Chief Business Officer | Direct | Buy | 11182025 | 20.46 | 17,500 | 358,050 | 1,176,286 | Form |
| 8 | Daughton, Michael | Chief Business Officer | Direct | Buy | 11182025 | 20.15 | 2,500 | 50,375 | 805,839 | Form |
| 9 | Daughton, Michael | Chief Business Officer | Direct | Buy | 11182025 | 20.16 | 4,354 | 87,777 | 755,839 | Form |
| 10 | Daughton, Michael | Chief Business Officer | Direct | Buy | 11182025 | 19.95 | 10,167 | 202,832 | 661,103 | Form |
| 11 | Daughton, Michael | Chief Business Officer | Direct | Buy | 11182025 | 19.39 | 15,479 | 300,138 | 445,408 | Form |
| 12 | Pinetree, Capital Ltd | See footnotes | Buy | 11142025 | 20.23 | 18,933 | 383,015 | 16,531,005 | Form | |
| 13 | Pinetree, Capital Ltd | See footnotes | Buy | 11142025 | 20.41 | 21,035 | 429,324 | 16,291,670 | Form | |
| 14 | Pinetree, Capital Ltd | See footnotes | Buy | 11142025 | 19.94 | 8,935 | 178,164 | 15,497,069 | Form | |
| 15 | Harse, David | General Manager Patient Care | Direct | Sell | 8152025 | 27.40 | 1,744 | 47,786 | 494,789 | Form |
| 16 | MacIntyre, Vita | Controller | Direct | Sell | 7282025 | 24.94 | 335 | 8,355 | 52,125 | Form |
| 17 | L6, Holdings Inc | See footnotes (3)(4)(5) | Buy | 5232025 | 24.01 | 25,000 | 600,250 | 48,140,050 | Form | |
| 18 | L6, Holdings Inc | See footnotes (3)(4)(5) | Buy | 5232025 | 23.98 | 15,000 | 359,700 | 47,480,400 | Form | |
| 19 | L6, Holdings Inc | See footnotes (3)(4)(5) | Buy | 5232025 | 24.30 | 40,000 | 972,000 | 47,749,500 | Form | |
| 20 | Fowler, Christopher L | President and CEO | Direct | Sell | 5202025 | 25.05 | 6,000 | 150,300 | 3,283,804 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.